PRQR — ProQR Therapeutics N.V.
$1.34+8.06%
Last close: · regular session
Last 60 sessions
PRQR closed at $1.34 (+8.06%) on Oct 27, 2026. Float: 64.4M shares. Latest SEC filing: 6-K on Oct 28, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PRQR in the TickerWise workspace.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
- Exchange: NASDAQ
- Employees: 166
- Website: https://www.proqr.com
Latest SEC filings for PRQR
Latest PRQR news
- ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences Read article
- ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease Read article
- ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.